Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease
Open Access
- 1 February 2011
- journal article
- Published by Springer Science and Business Media LLC in Fibrogenesis & Tissue Repair
- Vol. 4 (1), 4
- https://doi.org/10.1186/1755-1536-4-4
Abstract
Background: Connective tissue growth factor (CTGF) is widely thought to promote the development of fibrosis in collaboration with transforming growth factor (TGF)-β; however, most of the evidence for its involvement comes from correlative and culture-based studies. In this study, the importance of CTGF in tissue fibrosis was directly examined in three murine models of fibrotic disease: a novel model of multiorgan fibrosis induced by repeated intraperitoneal injections of CTGF and TGF-β2; the unilateral ureteral obstruction (UUO) renal fibrosis model; and an intratracheal bleomycin instillation model of pulmonary fibrosis. Results: Intraperitoneal coadministration of CTGF and TGF-β2 elicited a profound fibrotic response that was inhibited by the human anti-CTGF antibody FG-3019, as indicated by the ability of FG-3019 to ameliorate the histologic signs of fibrosis and reduce the otherwise increased hydroxyproline:proline (Hyp:Pro) ratios by 25% in kidney (P < 0.05), 30% in liver (P < 0.01) and 63% in lung (P < 0.05). Moreover, administration of either cytokine alone failed to elicit a fibrotic response, thus demonstrating that CTGF is both necessary and sufficient to initiate fibrosis in the presence of TGF-β and vice versa. In keeping with this requirement for CTGF function in fibrosis, FG-3019 also reduced the renal Hyp:Pro response up to 20% after UUO (P < 0.05). In bleomycin-injured animals, a similar trend towards a FG-3019 treatment effect was observed (38% reduction in total lung Hyp, P = 0.056). Thus, FG-3019 antibody treatment consistently reduced excessive collagen deposition and the pathologic severity of fibrosis in all models. Conclusion: Cooperative interactions between CTGF and TGF-β signaling are required to elicit overt tissue fibrosis. This interdependence and the observed anti-fibrotic effects of FG-3019 indicate that anti-CTGF therapy may provide therapeutic benefit in different forms of fibroproliferative disease.Keywords
This publication has 52 references indexed in Scilit:
- Connective Tissue Growth Factor Promotes Fibrosis Downstream of TGFb and IL-6 in Chronic Cardiac Allograft RejectionAmerican Journal of Transplantation, 2010
- Lost in translation; from animal models of pulmonary fibrosis to human diseaseRespirology, 2009
- Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivoJournal of Cell Communication and Signaling, 2009
- Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?Journal of Cell Communication and Signaling, 2009
- The Role of Tumor Cell–Derived Connective Tissue Growth Factor (CTGF/CCN2) in Pancreatic Tumor GrowthCancer Research, 2009
- Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio‐marker of fibroproliferative disease?Journal of Cell Communication and Signaling, 2009
- Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivoWound Repair and Regeneration, 2008
- The differential regulation of Smad7 in kidney tubule cells by connective tissue growth factor and transforming growth factor‐beta1Nephrology, 2007
- Adhesive Postoperative Small Bowel Obstruction: Incidence and Risk Factors of Recurrence After Surgical TreatmentAnnals of Surgery, 2006
- Connective tissue growth factor causes persistent proα2(I) collagen gene expression induced by transforming growth factor‐β in a mouse fibrosis modelJournal of Cellular Physiology, 2004